cardiovascluar disease

City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders.

By Frank Vinluan

BioPharma, Pharma

DNA molecular structure with sequencing data of human genome analysis.

CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO

Scribe Therapeutics’ IPO will support a pipeline led by a genetic medicine that represses expression of its target gene without making permanent changes. Common chronic cardiometabolic conditions are Scribe’s initial focus as the biotech works to bring genetic medicines beyond rare diseases.

By Frank Vinluan